CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $105 million in its first quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.20 per share.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.35 per share.

The biopharmaceutical company posted revenue of $210.8 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $203.5 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRPT at https://www.zacks.com/ap/SRPT

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News